Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Angina Pectoris Drugs Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The angina pectoris drugs market size has demonstrated strong growth in recent years. Its value is expected to expand from $12.88 billion in 2025 to $13.63 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.8%. This historical growth can be linked to factors such as the increasing occurrence of coronary heart disease, heightened awareness of angina symptoms, the introduction of beta-blockers, the expansion of hospital infrastructure, and the growing adoption of calcium channel blockers.
The angina pectoris drugs market is anticipated to demonstrate robust growth in the near future. The market is set to expand to $17.67 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.7%. This expansion during the projection period stems from factors such as advancements in precision medicine, an increase in wearable cardiac monitoring devices, a heightened need for combination therapies, greater investment in research and development for anti-ischemic agents, and the integration of telehealth in cardiac care. Key trends expected over the forecast horizon encompass personalized angina management, the development of minimally invasive drug delivery systems, the adoption of fixed-dose combination therapies, an expanding geriatric patient demographic, and the wider use of telemedicine and remote cardiac monitoring.
Get A Free Sample Report With In-Depth Market Insights:
Angina Pectoris Drugs Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The escalating incidence of cardiovascular diseases is anticipated to fuel the expansion of the angina pectoris drug market moving forward. These diseases encompass various conditions impacting the heart and blood vessels, including coronary artery disease, high blood pressure, heart failure, and stroke. The growing prevalence of cardiovascular diseases can be attributed to several factors, such as an aging population, unhealthy lifestyles, and the obesity epidemic. Angina pectoris medications, like nitrates, beta-blockers, and calcium channel blockers, effectively ease chest pain and discomfort resulting from insufficient blood flow to the heart, thereby enhancing patients’ overall quality of life. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 in 2023. Thus, the increasing prevalence of cardiovascular diseases is propelling the growth of the angina pectoris drug market.
Angina Pectoris Drugs Market Segment Analysis And Revenue Potential
The angina pectoris drugs market covered in this report is segmented –
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates
2) By Antiplatelet Agents: Aspirin, Clopidogrel
3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers
5) By Anti-Ischemic Agents: Ranolazine, Ivabradine
6) By Statins: Atorvastatin, Rosuvastatin
Angina Pectoris Drugs Market Innovation Trends Shaping Future Development
Leading companies in the angina pectoris drug market are concentrating on embracing novel technologies to maintain their market standing, exemplified by the U.S. Food and Drug Administration’s approval of Labetalol Hydrochloride Injection for angina treatment to better serve current consumers. Additionally, Nitrostat (Nitroglycerin Sublingual Tablets) has been authorized by the United States Food and Drug Administration (FDA) for the immediate management or acute prevention of angina pectoris. As an illustration, in March 2023, Hikma Pharmaceuticals PLC, a pharmaceutical firm based in the UK, introduced Labetalol Hydrochloride Injection, USP, in a prefilled syringe. This specific product has been sanctioned by the Food and Drug Administration of the United States. Within hospital settings, 10 mg/2 mL PFS is utilized for managing severe hypertension and reducing blood pressure.
Angina Pectoris Drugs Market Key Players Shaping Industry Direction
Major companies operating in the angina pectoris drugs market are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., GlaxoSmithKline plc, Lupin Pharmaceuticals Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Servier Laboratories, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., H. Lundbeck A/S
View The Full Angina Pectoris Drugs Market Report:
Angina Pectoris Drugs Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the angina pectoris drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model